Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups

Hindricks, 2021, 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS), Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Ruff, 2010, Am Heart J, 160, 635, 10.1016/j.ahj.2010.06.042 Lip, 2019, The safety of NOACs in atrial fibrillation patient subgroups: a narrative review, Int J Clin Pract, 73, e13285, 10.1111/ijcp.13285 Ferreira, 2018, Individualizing treatment choices in the systolic blood pressure intervention trial, J Hypertens, 36, 428, 10.1097/HJH.0000000000001535 Pocock, 2014, Individualizing treatment choices using quantitative methods, Am Heart J, 168, 607, 10.1016/j.ahj.2014.08.003 Hayward, 2006, Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis, BMC Med Res Methodol, 6, 18, 10.1186/1471-2288-6-18 Kent, 2020, The predictive approaches to treatment effect heterogeneity (PATH) statement, Ann Intern Med., 172, 35, 10.7326/M18-3667 Zelniker, 2021, Comparison of the efficacy and safety outcomes of Edoxaban in 8040 women versus 13 065 men with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial, Circulation, 143, 673, 10.1161/CIRCULATIONAHA.120.052216 Plitt, 2020, Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial, Int J Cardiol, 304, 185, 10.1016/j.ijcard.2020.01.009 Qamar, 2019, Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease, J Am Coll Cardiol, 74, 179, 10.1016/j.jacc.2019.04.061 Kato, 2016, Efficacy and safety of Edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial, J Am Heart Assoc, 5, 10.1161/JAHA.116.003432 Steffel, 2016, Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis, J Am Coll Cardiol, 68, 1169, 10.1016/j.jacc.2016.06.034 Bohula, 2016, Impact of renal function on outcomes with Edoxaban in the ENGAGE AF-TIMI 48 trial, Circulation, 134, 24, 10.1161/CIRCULATIONAHA.116.022361 Rost, 2016, Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48), Stroke, 47, 2075, 10.1161/STROKEAHA.116.013540 Xu, 2016, Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis From the ENGAGE AF-TIMI48 trial, J Am Heart Assoc, 5, 10.1161/JAHA.115.002587 O'Donoghue, 2015, Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationdagger, Eur Heart J, 36, 1470, 10.1093/eurheartj/ehv014 Magnani, 2016, Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48, Eur J Heart Fail, 18, 1153, 10.1002/ejhf.595 De Caterina, 2017, Valvular heart disease patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 trial, J Am Coll Cardiol, 69, 1372, 10.1016/j.jacc.2016.12.031 Fanola, 2018, Efficacy and safety of Edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial, J Am Heart Assoc, 7, 10.1161/JAHA.118.008987 Zelniker, 2019, Edoxaban in atrial fibrillation patients with established coronary artery disease: insights from ENGAGE AF-TIMI 48, Eur Heart J Acute Cardiovasc Care, 8, 176, 10.1177/2048872618790561 Chao, 2019, Clinical outcomes, Edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial, Eur Heart J, 40, 1518, 10.1093/eurheartj/ehy807 Boriani, 2021, Edoxaban versus Warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 Trial, Thromb Haemost, 121, 140, 10.1055/s-0040-1716540 Piccini, 2013, Circulation, 127, 224, 10.1161/CIRCULATIONAHA.112.107128 Kirchhof, 2016, ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 Yasuda, 2019, Antithrombotic therapy for atrial fibrillation with stable coronary disease, N Engl J Med, 381, 1103, 10.1056/NEJMoa1904143 De Caterina, 2014, What is 'valvular' atrial fibrillation? A reappraisal, Eur Heart J, 35, 3328, 10.1093/eurheartj/ehu352 Mosarla, 2019, Anticoagulation strategies in patients with cancer: JACC review topic of the week, J Am Coll Cardiol, 73, 1336, 10.1016/j.jacc.2019.01.017 Okumura, 2020, Low-dose Edoxaban in very elderly patients with atrial fibrillation, N Engl J Med, 383, 1735, 10.1056/NEJMoa2012883 Steffel, 2021, Double-blind comparison of half-dose versus full-dose Edoxaban in 14,014 patients with atrial fibrillation, J Am Coll Cardiol, 77, 1197, 10.1016/j.jacc.2020.12.053 de Groot, 2021, Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: a secondary analysis of the ENGAGE AF-TIMI 48 study, Am Heart J, 235, 132, 10.1016/j.ahj.2021.01.013 Fanola, 2017, A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial, Eur Heart J, 38, 888 Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Vranckx, 2019, Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial, Lancet, 394, 1335, 10.1016/S0140-6736(19)31872-0 Goette, 2016, Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial, Lancet, 388, 1995, 10.1016/S0140-6736(16)31474-X Moll, 2018, Edoxaban plus Aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial, J Endovasc Ther, 25, 158, 10.1177/1526602818760488 Van Mieghem, 2018, Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial, Am Heart J, 205, 63, 10.1016/j.ahj.2018.07.006 Colonna, 2020, Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study, Clin Cardiol, 43, 769, 10.1002/clc.23379 Hohnloser, 2019, Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial, Eur Heart J, 40, 3013, 10.1093/eurheartj/ehz190 Inoue, 2018, Prospective observational study in elderly patients with non-valvular atrial fibrillation: rationale and design of the All Nippon AF In the elderly (ANAFIE) registry, J Cardiol, 72, 300, 10.1016/j.jjcc.2018.02.018 Ohashi, 2018, Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry), BMJ Open, 8, 10.1136/bmjopen-2017-018910 Salazar, 2012, Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation, Thromb Haemost, 107, 925, 10.1160/TH11-08-0566 Ruff, 2015, Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial, Lancet, 385, 2288, 10.1016/S0140-6736(14)61943-7 Yin, 2018, Linking endogenous factor Xa Activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial, Circulation, 138, 1963, 10.1161/CIRCULATIONAHA.118.033933 de Groot, 2021, Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study, Eur Heart J Cardiovasc Pharmacother, 7, f30, 10.1093/ehjcvp/pvaa079 De Caterina, 2019, The global Edoxaban treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design, Clin Cardiol, 42, 1147, 10.1002/clc.23279